Breaking News

COSMO Pharmaceuticals SA (0RGI)

Symbol	Exchange	Currency
COPN	Switzerland	CHF	Delayed
COPNz	BATS Europe	CHF	Delayed
0RGI	London	CHF	Real-time

Add to/Remove from Watchlist Add to Watchlist

74.50 +20.00 +36.70%

10:41:01 - Closed. Currency in CHF ( Disclaimer )

Type: Equity

Market: United Kingdom

ISIN: NL0011832936

SEDOL: BYZY747

Volume: 1,127
Bid/Ask: 0.00 / 0.00
Day's Range: 74.30 - 75.40

Cosmo Pharmaceuticals NV Company Profile

Get an in-depth profile of COSMO Pharmaceuticals SA, including a general overview of the company's business and key management, as well as employee data and location and contact information.

IndustryPharmaceuticals

SectorHealthcare

Employees

319

Equity Type

DRC

Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, a submucosal injectable composition to allow endoscopists with a faster and less risky excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Relafalk, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers’ diarrhoea; and Byfavo, an intravenous benzodiazepine sedative/anesthetic. It is also developing Breezula, a novel androgen receptor inhibitor, which is in Phase III trials and targets androgen receptors in the scalp; Rifamycin SV MMX – IBS-D, a formulation that is in Phase III clinical trial to treat colonic infections and irritable bowel syndrome with diarrhoea; CB-03-10, an oral androgen receptor antagonist, which is in Phase I clinical trial for treatment solid tumors; CB-01-33 that is in preclinical studies for the treatment of bile acid diarrhea; and CB-01-35, an enema solution, which is in Phase II clinical trial for the treatment of distal ulcerative colitis and proctitis. The company has development, distribution, and licensing agreements with Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, RedHill Biopharma Ltd., Sun Pharmaceutical Industries Ltd., 3SBio, InfectoPharm, and Hyphens Pharma International Limited. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

Contact Information

Address Riverside II Sir John Rogerson’s Quay
Dublin, 2
Ireland

Phone 353 1 817 0370

Fax -

Web www.cosmopharma.com

Top Executives

Name	Age	Since	Title
Alessandro Repici	-	-	Member of Scientific Advisory Board
Alessandro E. Della Cha	61	2006	Executive Chairman
Geert D’Haens	-	-	Member of Scientific Advisory Board
Mauro Severino Ajani	69	2006	Founder & Non-Executive Director
Maria Grazia Roncarolo	70	2012	Non-Executive Director
Simon P. L. Travis	-	-	Member of Scientific Advisory Board
William J. Sandborn	61	-	Member of Scientific Advisory Board
Silvio Danese	-	-	Member of Scientific Advisory Board
Niall Donnelly	52	2016	Executive Director & CFO
Ralf Kiesslich	-	-	Member of Scientific Advisory Board
Michael Wallace	-	-	Member of Scientific Advisory Board
Robert Steffen	-	-	Member of Scientific Advisory Board
Silvana Perretta	51	2024	Non-Executive Director
John O’Dea	62	2024	Non-Executive Director
Giovanni Di Napoli	50	2024	Chief Executive Officer & Director

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:

Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
Only English comments will be allowed.
Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I have read Investing.com's comments guidelines and agree to the terms described.

I Agree

COPN Comments

Write your thoughts about Cosmo Pharmaceuticals NV

Are you sure you want to delete this chart?

Delete Cancel

Post

Post also to:

Replace the attached chart with a new chart ?

Replace Cancel

1000

Comment Guidelines

Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.

Please wait a minute before you try to comment again.

Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.

<div id="comment">
				<div class="comment js-comment" data-comment-id="{commentID}" id="comment-{commentID}" data-user-id="">
    <div class="mainComment js-content">
       <div class="commentInnerWrapper">
        <a href="{userLink}" class="js-user-link"><img src="{userImage}" width="33" height="33" alt="{usernameAlt}" class="img" onerror="this.src='https://i-invdn-com.investing.com/defaultUserMaleTmp.png';"></a><div class="commentBody">
                					<span class="commentUsername">
                    	<a href="{userLink}" class="js-user-link js-user-name">{username}</a>
					</span>
                                <span class="js-date" comment-date="{dateFormat}" comment-date-formatted="{dateFormatted}" title="{dateTitle}">Just Now</span>
                <div class="commentDropDown js-commentDropDownWrapper " data-user-id="" data-cid="{commentID}">
	<a href="javascript:void(0);" class="threeDotsIconSmall js-thinDropdownArrow"></a>
	<div class="tooltipPopup commentActionsPop noHeader js-commentDropDownOptions displayNone">
		<div class="addRow js-option share">
			<a href="javascript:void(0);" class="js-commentSharePopup" data-cid="{commentID}" data-curl="{commentLink}"><span class="smallShareIcon middle"></span>Share</a>
		</div>

<div class="js-option addRow follow">
            <div class="js-follow-post-button" data-reg_ep="follow comment">
                <span class="alertfollowIcon middle"></span>Follow this post            </div>
            <div class="js-unfollow-post-button displayNoneImp">
                <span class="alertUnfollowIcon middle"></span>Unfollow this post            </div>
        </div>

<div class="addRow js-option save"  data-reg_ep="save comment">
		<a href="javascript:void(0);" class="js-save-item-btn" data-item-type="comments" data-item-id="{commentID}">
			<i class="saveItemBigIcon middle"></i>
			Save		</a>
	</div>
	<div class="addRow saveItemsConfirmation noHover displayNone js-saveItemResult">
		
<div class="content js-saveItemSuccess displayNone">
	<span class="mediumGreenSuccessIcon"></span><span>Saved. See <a href="/members-admin/saved-items" target="_blank">Saved Items</a>.</span>
	<a href="javascript:void(0);" class="bugCloseIcon js-close"></a>
</div>
<div class="content js-saveItemAlreadySaved saveItemAlreadySaved displayNoneImp">
	<span>This comment has already been saved in your <a href="/members-admin/saved-items" target="_blank">Saved Items</a></span>
	<a href="javascript:void(0);" class="bugCloseIcon js-close"></a>
</div>
	</div>

<div class="addRow shareButtons js-sharePopup displayNone">
			<div class="js-shareComment"><span class="js-shareCommentSpan"></span></div>
		</div>
	</div>
</div>
                 <div class="commentAuthor js-comment-by-author"><span class="commentAuthorIcon"></span>Author's response</div>             </div>
		<div id="commentText-{commentID}" class="js-text-wrapper commentText withImage">
							<div id="commentBigChart{commentID}" class="commentBigChart js-comment-chart" onclick="openViewChartPopup('{commentID}')">
					<img src="https://d1-invdn-com.investing.com/comments_images/{commentImage}" alt="{commentAlt}">
					<i class="newMagnifyChartIcon"></i>
				</div>
						<span class="js-text">{commentContent}</span>
			<div class="clear"></div>
							<div class="commentButtons js-not-master-user">
					<a href="javascript:void(0)" class="reply js-reply-btn" data-real-parent-id="{commentID}" data-to-user-name="{username}" data-to-user-id="">Reply</a>
					<div class="inlineblock likeDislikeBox js-like-dislike-box" data-item-id="{commentID}">
	<input class="js-like-checkbox" type="checkbox" name="option" value="Yes" id="like_{commentID}">
	<label for="like_{commentID}" class="like" title="I agree"></label>
	<span class="numOfLikes js-like-count lighterGrayFont">0</span>
	<input class="js-dislike-checkbox" type="checkbox" name="option" value="No" id="dislike_{commentID}">
	<label for="dislike_{commentID}" class="dislike" title="I disagree"></label>
	<span class="numOfDislikes js-dislike-count lighterGrayFont">0</span>
</div>

<div class="reportComment js-flag float_lang_base_2">
                            <a href="javascript:void(0);" id="commentFlag_{commentID}">
                                <span class="reportCommentIcon middle"></span><span class="inlineblock middle">Report</span>
                            </a>
                        </div>
                    				</div>
					</div>
	   </div>
	</div>
	</div>			</div>
			<div id="reply">
				
    <div class="commentReply js-comment js-comment-reply" data-comment-id="{commentID}" id="comment-{commentID}" data-user-id="">
		<div class="commentInnerWrapper"><a href="{userLink}" class="js-user-link"><img src="{userImage}" width="33" height="33" alt="{usernameAlt}" class="img" onerror="this.src='https://i-invdn-com.investing.com/defaultUserMaleTmp.png';"></a><div class="commentBody js-content">
            				<span class="commentUsername">
					<a href="{userLink}" class="commentUsername js-user-link js-user-name" onMouseOver="">{username}</a>
				</span>
                        <span class="js-date" comment-date="{dateFormat}" comment-date-formatted="{dateFormatted}" title="{dateTitle}">Just Now</span>
			 <div class="commentAuthor js-comment-by-author"><span class="commentAuthorIcon"></span>Author's response</div> 			<div class="commentDropDown js-commentDropDownWrapper " data-user-id="" data-cid="{commentID}">
	<a href="javascript:void(0);" class="threeDotsIconSmall js-thinDropdownArrow"></a>
	<div class="tooltipPopup commentActionsPop noHeader js-commentDropDownOptions displayNone">
		<div class="addRow js-option share">
			<a href="javascript:void(0);" class="js-commentSharePopup" data-cid="{commentID}" data-curl="{commentLink}"><span class="smallShareIcon middle"></span>Share</a>
		</div>

</div>
		<div id="commentText-{commentID}" class="js-text-wrapper commentText withImage">
							<div id="commentBigChart{commentID}" class="replyBigChart displayNone js-comment-chart">
					<img src="https://d1-invdn-com.investing.com/comments_images/{commentImage}" alt="{commentAlt}">
					<i class="newMagnifyChartIcon"></i>
				</div>
				<span id="commentSmallChart{commentID}" class="commentSmallChart pointer js-comment-chart" onclick="openViewChartPopup('{commentID}')">
                    <img src="https://d1-invdn-com.investing.com/comments_images/{commentImageSmall}" width="116" height="52" alt="{commentAlt}">
                    <span class="chartMagnifyOverlay displayNone"></span>
                    <span class="searchGlassIcon chartMagnify displayNone"></span>
                </span>
						<span class="js-text">{commentContent}</span>
			<div class="clear"></div>
							<div class="commentButtons js-not-master-user">
					<a href="javascript:void(0)" class="reply js-reply-btn" data-real-parent-id="{commentID}" data-to-user-name="{username}" data-to-user-id="">Reply</a>
					<div class="inlineblock likeDislikeBox js-like-dislike-box" data-item-id="{commentID}">
	<input class="js-like-checkbox" type="checkbox" name="option" value="Yes" id="like_{commentID}">
	<label for="like_{commentID}" class="like" title="I agree"></label>
	<span class="numOfLikes js-like-count lighterGrayFont">0</span>
	<input class="js-dislike-checkbox" type="checkbox" name="option" value="No" id="dislike_{commentID}">
	<label for="dislike_{commentID}" class="dislike" title="I disagree"></label>
	<span class="numOfDislikes js-dislike-count lighterGrayFont">0</span>
</div>

Are you sure you want to delete this chart?

Delete Cancel

Post

Replace the attached chart with a new chart ?

Replace Cancel

1000

Comment Guidelines

Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.

Please wait a minute before you try to comment again.

I feel that this comment is:

Spam

Offensive

Thank You!

Your report has been sent to our moderators for review

More Categories

1D1W1M6M1Y5YMax

US 30	38,686.3	-181.7	-0.47%
US 500	5,360.7	-0.1	0.00%
Dow Jones	38,685.46	-182.58	-0.47%
S&P 500	5,360.54	-0.25	0.00%
Nasdaq	17,273.07	+80.54	+0.47%
S&P 500 VIX	12.84	+0.10	+0.78%
Dollar Index	104.850	-0.262	-0.25%

Crude Oil WTI	77.97	+0.23	+0.30%
Brent Oil	81.98	+0.35	+0.43%
Natural Gas	3.099	+0.193	+6.64%
Gold	2,331.20	+4.20	+0.18%
Silver	29.310	-0.564	-1.89%
Copper	4.5147	-0.0288	-0.63%
US Soybeans	1,177.38	-9.62	-0.81%

U.S. 10Y	4.405	-0.066	-1.48%
U.S. 30Y	4.541	-0.054	-1.17%
U.S. 5Y	4.425	-0.059	-1.31%
U.S. 3M	5.395	+0.015	+0.28%
US 10Y T-Note	109.50	+0.41	+0.37%
Euro Bund	130.32	+0.66	+0.51%
10-2 Yield Spread	-41.56	+4.18	+-9.14%

Apple	204.86	+11.74	+6.08%
Alphabet A	175.53	+0.52	+0.30%
Tesla	169.75	-4.04	-2.32%
Amazon.com	185.76	-1.30	-0.69%
Netflix	645.15	+0.65	+0.10%
Meta Platforms	503.76	+1.16	+0.23%
Bank of America	38.81	-0.87	-2.18%

Recent Quotes

	Name	Price	Chg.	Chg. %
	0RGI	74.50	+20.00	+36.70%

Market Movers

Name	Last	Chg. %	Vol.
NVDA	120.67	-0.92%	169.74M
AAPL	204.82	+6.06%	123.78M
TSLA	169.73	-2.34%	49.56M
AMD	158.78	-0.97%	30.11M
AMZN	185.75	-0.70%	15.17M
MSFT	429.61	+0.41%	6.12M
META	503.89	+0.26%	5.16M

Name	Last	Chg. %	Vol.
AAPL	204.61	+5.95%	123.57M
FSLR	292.57	+4.57%	2.81M
ILMN	113.86	+3.68%	1.38M
FMC	56.85	+3.38%	2.37M
VFC	13.57	+3.08%	4.57M
PARA	12.33	+2.88%	6.82M
ORLY	1,000.00	+2.55%	370.94K

Name	Last	Chg. %	Vol.
NEE	72.34	-6.02%	14.76M
LUV	28.28	-4.76%	7.02M
STT	71.46	-3.89%	1.46M
APTV	76.83	-3.55%	1.12M
C	59.35	-3.39%	9.35M
SYF	42.85	-3.37%	1.80M
PYPL	64.89	-3.27%	9.74M

Webinars

Profit from Mean Reversion with Candlesticks and Oscillators Thursday, June 13, 2024 | 08:00AM EDT

Intraday Trading Made Easy With this Explosive ORB Strategy Thursday, June 20, 2024 | 08:00AM EDT